Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Sales | 625 | 1,362 | 3,644 | 1,399 | 13,696 |
| Gross Profit | 625 | 1,362 | 3,644 | 1,399 | 13,696 |
| Operating Expenses | 23,048 | 25,803 | 24,086 | 21,692 | 20,401 |
| Operating Income | -22,423 | -24,441 | -20,442 | -20,293 | -6,705 |
| Other Income | 109 | 5 | 19 | 12 | -33 |
| Pre-tax Income | -22,314 | -24,436 | -20,423 | -20,281 | -6,738 |
| Income Tax | 9 | N/A | 23 | 26 | 92 |
| Net Income Continuous | -22,323 | -24,436 | -20,446 | -20,307 | -6,830 |
| Net Income | $-22,323 | $-24,436 | $-20,446 | $-20,307 | $-6,830 |
| EPS Basic Total Ops | -6.75 | -9.25 | -7.77 | -7.75 | -2.50 |
| EPS Basic Continuous Ops | -6.79 | -9.26 | -7.76 | -7.72 | -2.60 |
| EPS Diluted Total Ops | -6.75 | -9.25 | -7.77 | -7.75 | -2.50 |
| EPS Diluted Continuous Ops | -6.79 | -9.26 | -7.76 | -7.72 | -2.60 |
| EBITDA(a) | $-21,986 | $-23,929 | $-19,548 | $-19,732 | $-6,147 |